GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

This is believed to be the first U.S. positive for tulobuterol, a drug from the same family as clenbuterol and albuterol.

Anticoagulants, which reduce the blood’s ability to clot, are only a “good thing” to take if you are at a high risk for a ...

Dr. Roach shares a link to a video, but having your doctor watch you use it is the best way to verify you're doing it right.

Albuterol (also known as salbutamol) is a short-acting bronchodilator. It is used in emergency situations or for quick relief use as needed. Bronchodilators work by relaxing and opening the airways to ...

GSK plc announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation ...

· If approved, this next-generation low carbon salbutamol has the potential to reduce greenhouse gas emissions by 92%3 per inhaler · GSK will proceed with regulatory submissions, with launch expected ...

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. The recent approval of albuterol/budesonide could change the way that mild asthma is treated in ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations compared with albuterol alone for people with normally mild asthma, the phase ...

We examined the effect of nebulized high-dose (75 or 150 mg/hr) albuterol for status asthmaticus in children admitted to our PICU. Hemodynamic changes (tachycardia, lower MAP, and lower DBP) were the ...

President Joe Biden’s career-defining victories over Big Pharma — reforming Medicare to lower prices and capping inhaler costs for millions of Americans with lung disease — are facing an unlikely ...